Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with …

M Gatti, F Pea - Expert Review of Anti-infective Therapy, 2023 - Taylor & Francis
Introduction The choice of best therapeutic strategy for difficult-to-treat resistance (DTR)
Gram-negative infections currently represents an unmet clinical need. Areas covered This …

Current perspectives on the diagnosis and management of healthcare-associated ventriculitis and meningitis

M Karvouniaris, A Brotis, K Tsiakos, E Palli… - Infection and Drug …, 2022 - Taylor & Francis
Ventriculitis or post-neurosurgical meningitis or healthcare-associated ventriculitis and
meningitis (VM) is a severe infection that complicates central nervous system operations or …

Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections

M Gatti, F Pea - Current Opinion in Infectious Diseases, 2021 - journals.lww.com
Although available data are still limited, real-world evidence regarding mainly ceftolozane-
tazobactam and ceftazidime-avibactam could support the administration of novel beta …

Extended and continuous infusion of novel protected β-lactam antibiotics: a narrative review

F Venuti, M Trunfio, AG Martson, F Lipani… - Drugs, 2023 - Springer
Consolidated data from pharmacokinetic and pharmacodynamic studies support the
administration of β-lactam antibiotics in prolonged infusion (ie, extended or continuous) to …

The blood–brain barrier and pharmacokinetic/pharmacodynamic optimization of antibiotics for the treatment of central nervous system infections in adults

N Haddad, M Carr, S Balian, J Lannin, Y Kim, C Toth… - Antibiotics, 2022 - mdpi.com
Bacterial central nervous system (CNS) infections are serious and carry significant morbidity
and mortality. They encompass many syndromes, the most common being meningitis, which …

Healthcare-associated central nervous system infections

M Ippolito, A Giarratano… - Current Opinion in …, 2022 - journals.lww.com
Clinicians should maintain a high index of suspicion for healthcare-associated central
nervous system infections in patients with specific risk factors (ie recent neurosurgery …

Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa …

EK McCreary, KE Byers, C Fernandes… - Open Forum …, 2020 - academic.oup.com
We report a case of multidrug-resistant Pseudomonas aeruginosa meningitis treated with
ceftolozane-tazobactam with concomitant therapeutic drug monitoring of plasma and …

Antimicrobial use in central nervous system infections

F Ciummo, P Srinivas, J Biedny - Current Opinion in Infectious …, 2021 - journals.lww.com
Antimicrobial use in central nervous system infections : Current Opinion in Infectious Diseases
Antimicrobial use in central nervous system infections : Current Opinion in Infectious Diseases …

Central nervous system infections and antimicrobial resistance: an evolving challenge

R Nau, F Sörgel, H Eiffert - Current Opinion in Neurology, 2021 - journals.lww.com
Several antibiotics with a low to moderate toxicity (in particular, β-lactam antibiotics,
fosfomycin, trimethoprim-sulfamethoxazole, rifampicin, vancomycin) can be administered at …

New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections

R Nau, J Seele, H Eiffert - Antibiotics, 2024 - mdpi.com
Nosocomial central nervous system (CNS) infections with carbapenem-and colistin-resistant
Gram-negative and vancomycin-resistant Gram-positive bacteria are an increasing …